HUP0103329A3 - Expression and export of angiostatin and endostatin as immunofusis - Google Patents

Expression and export of angiostatin and endostatin as immunofusis

Info

Publication number
HUP0103329A3
HUP0103329A3 HU0103329A HUP0103329A HUP0103329A3 HU P0103329 A3 HUP0103329 A3 HU P0103329A3 HU 0103329 A HU0103329 A HU 0103329A HU P0103329 A HUP0103329 A HU P0103329A HU P0103329 A3 HUP0103329 A3 HU P0103329A3
Authority
HU
Hungary
Prior art keywords
immunofusis
endostatin
angiostatin
export
expression
Prior art date
Application number
HU0103329A
Other languages
English (en)
Original Assignee
Lexigen Pharmaceuticals Corp L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharmaceuticals Corp L filed Critical Lexigen Pharmaceuticals Corp L
Publication of HUP0103329A2 publication Critical patent/HUP0103329A2/hu
Publication of HUP0103329A3 publication Critical patent/HUP0103329A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HU0103329A 1998-08-25 1999-08-25 Expression and export of angiostatin and endostatin as immunofusis HUP0103329A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9788398P 1998-08-25 1998-08-25
PCT/US1999/019329 WO2000011033A2 (en) 1998-08-25 1999-08-25 Expression and export of angiostatin and endostatin as immunofusins

Publications (2)

Publication Number Publication Date
HUP0103329A2 HUP0103329A2 (hu) 2001-12-28
HUP0103329A3 true HUP0103329A3 (en) 2003-09-29

Family

ID=22265602

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103329A HUP0103329A3 (en) 1998-08-25 1999-08-25 Expression and export of angiostatin and endostatin as immunofusis

Country Status (20)

Country Link
US (3) US20030139365A1 (hu)
EP (1) EP1107989B1 (hu)
JP (3) JP2002523036A (hu)
CN (2) CN101386651A (hu)
AT (1) ATE462725T1 (hu)
AU (1) AU761027B2 (hu)
BR (1) BR9913331A (hu)
CA (1) CA2339331C (hu)
CZ (1) CZ302303B6 (hu)
DE (1) DE69942207D1 (hu)
DK (1) DK1107989T3 (hu)
ES (1) ES2342239T3 (hu)
HK (1) HK1042503A1 (hu)
HU (1) HUP0103329A3 (hu)
NO (1) NO20010918L (hu)
PL (1) PL202057B1 (hu)
PT (1) PT1107989E (hu)
RU (1) RU2240328C2 (hu)
WO (1) WO2000011033A2 (hu)
ZA (1) ZA200101290B (hu)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518304A (ja) * 1997-10-01 2001-10-16 ジー・ディー・サール・アンド・カンパニー アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用
EP1037927B1 (en) 1997-12-08 2004-05-19 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
HUP0103329A3 (en) * 1998-08-25 2003-09-29 Lexigen Pharmaceuticals Corp L Expression and export of angiostatin and endostatin as immunofusis
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DK1200479T3 (da) * 1999-08-09 2006-05-15 Emd Lexigen Res Ct Corp Multiple cytokin-antistof-komplekser
IL131803A0 (en) * 1999-09-08 2001-03-19 Genena Ltd Method for improving the efficiency of cancer gene therapy
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
DK1294401T3 (da) * 2000-06-29 2007-10-08 Merck Patent Gmbh Forbedring af antistof/cytokin-fusionsproteinmedierede immunresponser ved kombineret behandling med immuncytokin-optagelsesforberende midler
US6803211B2 (en) * 2000-08-25 2004-10-12 Pfizer Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
EP1197550A3 (en) * 2000-08-25 2002-11-20 Pfizer Products Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
ATE346607T1 (de) * 2000-09-01 2006-12-15 Philadelphia Health & Educatio Verfahren und zusammensetzungen zur inhibition der angiogenese
US7160858B2 (en) 2000-09-01 2007-01-09 Philadelphia, Health And Education Corporation Methods and compositions for inhibiting angiogenesis
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) * 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
EP2354791A1 (en) * 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
EP1501861A4 (en) * 2002-05-06 2007-06-20 Univ Texas TARGETED BINDING PROTEINS FOR THE ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC REAGENTS
BRPI0317376B8 (pt) * 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
KR20070030159A (ko) * 2003-08-29 2007-03-15 칠드런'즈 메디컬 센터 코포레이션 엔도스타틴의 ｎ-말단으로부터의 항-혈관형성 펩티드
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
RU2369616C2 (ru) 2003-12-30 2009-10-10 Мерк Патент Гмбх Слитые белки il-7
AU2004309063B2 (en) * 2003-12-31 2010-10-28 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
WO2005066348A2 (en) 2004-01-05 2005-07-21 Emd Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
WO2005070967A2 (en) 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
JP2005301419A (ja) * 2004-04-07 2005-10-27 Hitachi Ltd ディスクアレイ装置およびそのデータ処理方法
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
CA2591297C (en) * 2004-12-09 2015-01-13 Stephen D. Gillies Il-7 variants with reduced immunogenicity
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
EP1941043B1 (en) 2005-10-21 2011-04-13 F. Hoffmann-La Roche AG Method for the recombinant expression of a polypeptide
PL1966238T3 (pl) * 2005-12-30 2012-09-28 Merck Patent Gmbh Warianty interleukiny-12p40 o polepszonej stabilności
CN101351477B (zh) 2005-12-30 2011-11-16 默克专利有限公司 具有降低的免疫原性的抗cd19抗体
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
US7981446B2 (en) * 2007-11-26 2011-07-19 Forhumantech. Co., Ltd. Pharmaceutical compositions and methods for delivering nucleic acids into cells
AT506216B1 (de) 2008-02-13 2009-07-15 Peter Dr Hernuss Zusammensetzung zur aufnahme über mukoses gewebe
US20120093814A1 (en) * 2009-03-30 2012-04-19 Boehringer Ingelheim International Gmbh Fusion Proteins Comprising Canine FC Portions
MX2011011044A (es) 2009-04-22 2011-11-04 Merck Patent Gmbh Proteinas de fusion de anticuerpos con sitios de enlace de receptor fc neonatal (fcrn) modificados.
KR101579318B1 (ko) * 2010-04-29 2015-12-21 엘지전자 주식회사 태양 전지 및 그 제조 방법
US11492383B2 (en) 2011-06-24 2022-11-08 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
RU2465283C1 (ru) * 2011-06-27 2012-10-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвити Рекомбинантный гибридный полипептид, способный ингибировать пролиферацию эндотелиальных клеток человека in vitro, и способ его получения
EP2561888A1 (en) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
CN105393376B (zh) * 2013-06-14 2017-11-17 株式会社Lg化学 有机太阳能电池及其制造方法
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20160126391A1 (en) * 2014-10-31 2016-05-05 Byd Company Limited Solar cell module and manufacturing method thereof
JP6917368B2 (ja) * 2015-10-23 2021-08-11 アポジェニックス アーゲー 一本鎖ｃｄ２７受容体アゴニストタンパク質
EP3365363A1 (en) * 2015-10-23 2018-08-29 Apogenix AG Single-chain gitr-receptor agonist proteins
EP3365448A1 (en) * 2015-10-23 2018-08-29 Apogenix AG Single-chain cd137-receptor agonist proteins
JP7051697B2 (ja) 2015-12-03 2022-04-11 ハイデルベルク バイオテック ゲーエムベーハー 線維症又は線維症関連疾患を治療及び診断するための手段及び方法
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN109824779B (zh) * 2017-11-23 2023-05-26 中山大学 一种包含IgG的Fc结构域和EB病毒包膜糖蛋白胞外域的融合蛋白
EP4316502A2 (en) 2018-04-17 2024-02-07 Heidelberg Biotech GmbH Means and methods for the treatment of angiogenesis-, fibrosis- and cancer-related diseases with protein oligomers comprising nc-1-fc
US20220047710A1 (en) * 2018-09-12 2022-02-17 Washington University Single chain constructs
US20240100134A1 (en) * 2021-01-20 2024-03-28 Monash University Fusion proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271294A (ja) * 1992-01-24 1993-10-19 Japan Found Cancer Res ヒトプロヒビチンおよびそれをコードするｄｎａ
US5643783A (en) * 1993-12-01 1997-07-01 President And Fellows Of Harvard College Collagen and uses therefor
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5922852A (en) * 1995-06-07 1999-07-13 Oklahoma Medical Research Foundation 3' untranslated region of the human prohibitin gene
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
CN1202932A (zh) * 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
HUP0101343A3 (en) * 1998-04-17 2003-10-28 Lexigen Pharmaceuticals Corp L Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
KR20010052566A (ko) * 1998-06-03 2001-06-25 윌리엄 뉴 엔도스타틴 단백질을 포함하는 단백질 올리고머 조성물 및이의 사용방법
HUP0103329A3 (en) * 1998-08-25 2003-09-29 Lexigen Pharmaceuticals Corp L Expression and export of angiostatin and endostatin as immunofusis
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin

Also Published As

Publication number Publication date
CA2339331A1 (en) 2000-03-02
US20130165634A1 (en) 2013-06-27
US8206718B2 (en) 2012-06-26
CZ2001643A3 (cs) 2002-02-13
EP1107989B1 (en) 2010-03-31
US20070009538A1 (en) 2007-01-11
JP2009273478A (ja) 2009-11-26
JP2013128490A (ja) 2013-07-04
RU2240328C2 (ru) 2004-11-20
JP2002523036A (ja) 2002-07-30
CN100422332C (zh) 2008-10-01
NO20010918L (no) 2001-04-19
NO20010918D0 (no) 2001-02-23
PL346703A1 (en) 2002-02-25
CA2339331C (en) 2011-03-01
US20030139365A1 (en) 2003-07-24
DK1107989T3 (da) 2010-05-25
ZA200101290B (en) 2002-02-15
BR9913331A (pt) 2001-05-15
CN101386651A (zh) 2009-03-18
AU5583699A (en) 2000-03-14
EP1107989A2 (en) 2001-06-20
WO2000011033A2 (en) 2000-03-02
US8703908B2 (en) 2014-04-22
PL202057B1 (pl) 2009-05-29
CZ302303B6 (cs) 2011-02-16
AU761027B2 (en) 2003-05-29
ATE462725T1 (de) 2010-04-15
DE69942207D1 (de) 2010-05-12
ES2342239T3 (es) 2010-07-02
PT1107989E (pt) 2010-07-02
CN1326467A (zh) 2001-12-12
WO2000011033A3 (en) 2000-06-22
HK1042503A1 (zh) 2002-08-16
HUP0103329A2 (hu) 2001-12-28

Similar Documents

Publication Publication Date Title
HUP0103329A3 (en) Expression and export of angiostatin and endostatin as immunofusis
EP0996632A4 (en) ANGIOSTATIN FRAGMENTS AND METHOD FOR USING THEM
HUP0202705A3 (en) Methods and microorganisms or production of panto-compounds
GB2364059B (en) Beta-Secretase enzyme compositions and methods
AU3995799A (en) Methods and compositions for expression of transgenes in plants
EP0885308A4 (en) CONNECTIONS AND METHODS FOR THE PRODUCTION OF EMBRYONIC STEM CELLS
AU8602498A (en) Protective garment and method of manufacture
IL149078A0 (en) Modified plant viruses and methods of use thereof
ZA988332B (en) In planta transformation of plants
PL329308A1 (en) Derivatives of aminoisoquinoline and aminothienepyridine as well as their application as antinflammatory agents
EP1100136A4 (en) CELL AND METHOD FOR THE PRODUCTION THEREOF
HUP0201866A2 (en) Maize npr1 polynucleotides and methods of use
AU2454701A (en) Advanced alloy fiber and process of making
EP1109582A4 (en) METHOD FOR STRENGTHENING AND RESTRICTING GENE EXPRESSION
GB9814869D0 (en) Process and composition
GB0318113D0 (en) ›-Secretase enzyme compositions and methods
HUP0200528A2 (en) Novel plant genes and uses thereof
GB9807586D0 (en) Enzymes and their use
EP1155127A4 (en) METHOD FOR MODIFYING THE MORPHOLOGY, BIOCHEMISTRY AND PHYSIOLOGY OF PLANTS
PL331959A1 (en) Novel builder and pigment
HK1042089A1 (zh) 氮雜環縮肽及其作為殺寄生蟲劑的用途
IL134662A0 (en) Bisethers of 1-oxa, aza and thianaphthalen-2- ones as phospholamban inhibitors
AU4318699A (en) Plant retroelements and methods related thereto
GB9713852D0 (en) Plant genes and uses thereof
IL121719A (en) Deicing composition and process of production thereof